API | condoliase

condoliase (Hernicore) Report issue

Biological Experimental

AACT ChEMBL DrugBank

Active Ingredient History

NOW

Condoliase (Hernicore) is a biopharmaceutical for the treatment of lumbar disc herniation. Clinical trials have shown its benefit in alleviation lumbar disc herniation associated low back pain and disability, although some concerns have been suggested with regard to promotion of disc degeneration. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
condoliase

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

condoliase | si-6603

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Hernia (Phase 2/Phase 3)

Intervertebral Disc Displacement ()

Lumbar Vertebrae (Phase 3)

Spinal Diseases (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue